124 related articles for article (PubMed ID: 26122367)
1. ERG and FLI1 are useful immunohistochemical markers in phosphaturic mesenchymal tumors.
Tajima S; Takashi Y; Ito N; Fukumoto S; Fukuyama M
Med Mol Morphol; 2016 Dec; 49(4):203-209. PubMed ID: 26122367
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of Vascular Markers (Immunohistochemical Stains) in Soft Tissue Sarcomas.
Naeem N; Mushtaq S; Akhter N; Hussain M; Hassan U
J Coll Physicians Surg Pak; 2018 May; 28(5):352-356. PubMed ID: 29690962
[TBL] [Abstract][Full Text] [Related]
3. [Characteristics of ERG, Fli-1, CD34, CD31 and FⅧRAg expression in hepatic malignant vascular tumors].
Wang ZB; An XJ; Deng JF; Liu JH; Shi HY
Zhonghua Bing Li Xue Za Zhi; 2017 Nov; 46(11):760-763. PubMed ID: 29136688
[No Abstract] [Full Text] [Related]
4. ERG and FLI1 protein expression in epithelioid sarcoma.
Stockman DL; Hornick JL; Deavers MT; Lev DC; Lazar AJ; Wang WL
Mod Pathol; 2014 Apr; 27(4):496-501. PubMed ID: 24072183
[TBL] [Abstract][Full Text] [Related]
5. Synergistic Role of Endothelial ERG and FLI1 in Mediating Pulmonary Vascular Homeostasis.
Looney AP; Han R; Stawski L; Marden G; Iwamoto M; Trojanowska M
Am J Respir Cell Mol Biol; 2017 Jul; 57(1):121-131. PubMed ID: 28248553
[TBL] [Abstract][Full Text] [Related]
6. ERG protein expression in human tumors detected with a rabbit monoclonal antibody.
Yaskiv O; Rubin BP; He H; Falzarano S; Magi-Galluzzi C; Zhou M
Am J Clin Pathol; 2012 Dec; 138(6):803-10. PubMed ID: 23161713
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of ERG and FLI1 expression in endothelial cells triggers endothelial-to-mesenchymal transition.
Nagai N; Ohguchi H; Nakaki R; Matsumura Y; Kanki Y; Sakai J; Aburatani H; Minami T
PLoS Genet; 2018 Nov; 14(11):e1007826. PubMed ID: 30500808
[TBL] [Abstract][Full Text] [Related]
8. Atypical fibroxanthoma with pseudoangiomatous features: a histological and immunohistochemical mimic of cutaneous angiosarcoma.
Thum C; Husain EA; Mulholland K; Hornick JL; Brenn T
Ann Diagn Pathol; 2013 Dec; 17(6):502-7. PubMed ID: 24080496
[TBL] [Abstract][Full Text] [Related]
9. Phosphaturic mesenchymal tumors show positive staining for somatostatin receptor 2A (SSTR2A).
Houang M; Clarkson A; Sioson L; Elston MS; Clifton-Bligh RJ; Dray M; Ranchere-Vince D; Decouvelaere AV; de la Fouchardiere A; Gill AJ
Hum Pathol; 2013 Dec; 44(12):2711-8. PubMed ID: 24060005
[TBL] [Abstract][Full Text] [Related]
10. Possibility of D2-40 as a diagnostic and tumor differentiation-suggestive marker for some of phosphaturic mesenchymal tumors.
Tajima S; Fukayama M
Int J Clin Exp Pathol; 2015; 8(8):9390-6. PubMed ID: 26464693
[TBL] [Abstract][Full Text] [Related]
11. The utility of ERG, CD31 and CD34 in the cytological diagnosis of angiosarcoma: an analysis of 25 cases.
Sullivan HC; Edgar MA; Cohen C; Kovach CK; HooKim K; Reid MD
J Clin Pathol; 2015 Jan; 68(1):44-50. PubMed ID: 25352641
[TBL] [Abstract][Full Text] [Related]
12. Utility of immunohistochemical staining with FLI1, D2-40, CD31, and CD34 in the diagnosis of acquired immunodeficiency syndrome-related and non-acquired immunodeficiency syndrome-related Kaposi sarcoma.
Rosado FG; Itani DM; Coffin CM; Cates JM
Arch Pathol Lab Med; 2012 Mar; 136(3):301-4. PubMed ID: 22372906
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical and molecular detection of the expression of FGF23 in phosphaturic mesenchymal tumors including the non-phosphaturic variant.
Shiba E; Matsuyama A; Shibuya R; Yabuki K; Harada H; Nakamoto M; Kasai T; Hisaoka M
Diagn Pathol; 2016 Mar; 11():26. PubMed ID: 26956379
[TBL] [Abstract][Full Text] [Related]
14. Allosteric interference in oncogenic FLI1 and ERG transactions by mithramycins.
Hou C; Mandal A; Rohr J; Tsodikov OV
Structure; 2021 May; 29(5):404-412.e4. PubMed ID: 33275876
[TBL] [Abstract][Full Text] [Related]
15. EWS-FLI1, EWS-ERG, and EWS-ETV1 oncoproteins of Ewing tumor family all suppress transcription of transforming growth factor beta type II receptor gene.
Im YH; Kim HT; Lee C; Poulin D; Welford S; Sorensen PH; Denny CT; Kim SJ
Cancer Res; 2000 Mar; 60(6):1536-40. PubMed ID: 10749119
[TBL] [Abstract][Full Text] [Related]
16. CD56 may be a more useful immunohistochemical marker than somatostatin receptor 2A for the diagnosis of phosphaturic mesenchymal tumors.
Tajima S; Fukayama M
Int J Clin Exp Pathol; 2015; 8(7):8159-64. PubMed ID: 26339384
[TBL] [Abstract][Full Text] [Related]
17. FLI1 is a novel ETS transcription factor involved in gene fusions in prostate cancer.
Paulo P; Barros-Silva JD; Ribeiro FR; Ramalho-Carvalho J; Jerónimo C; Henrique R; Lind GE; Skotheim RI; Lothe RA; Teixeira MR
Genes Chromosomes Cancer; 2012 Mar; 51(3):240-9. PubMed ID: 22081504
[TBL] [Abstract][Full Text] [Related]
18. A SMARCB1-deficient vulvar neoplasm with prominent myxoid stroma: report of a case showing ERG and FLI1 expression.
Tajima S; Takahasi Y; Hikoaki M; Goto R
Int J Clin Exp Pathol; 2015; 8(6):7526-32. PubMed ID: 26261664
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic and molecular features of six cases of phosphaturic mesenchymal tumor.
Sun L; Dehner C; Kenney J; McNulty SM; Zhu X; Pfeifer JD; Maluf HM; Chrisinger JSA
Virchows Arch; 2021 Apr; 478(4):757-765. PubMed ID: 33151412
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical expression of Ets-related gene-transcriptional factor in adenocarcinoma prostate and its correlation with Gleason score.
Mannan R; Bhasin TS; Manjari M; Singh G; Bhatia PK; Sharma S
Indian J Pathol Microbiol; 2016; 59(4):489-495. PubMed ID: 27721279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]